Castle Biosciences (CSTL) Retained Earnings (2018 - 2026)

Castle Biosciences has reported Retained Earnings for 9 years, with the latest figure at $711.1 million in Q2 2026.

• Quarterly Retained Earnings rose 5.08% year-over-year to $711.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $711.1 million (up 5.08% YoY) and the FY2025 annual result came in at $694.9 million, up 5.97% from the prior year.
• Retained Earnings rose to $711.1 million in Q2 2026 per CSTL's latest filing, from $700.3 million in the prior quarter.
• Over five years, Retained Earnings peaked at $711.1 million in Q2 2026 and troughed at $515.7 million in Q1 2022.
• A 5-year average of $624.8 million and a median of $629.7 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings grew 11.57% in 2023, then gained 5.08% in 2026.
• Over 5 years, Retained Earnings stood at $560.4 million in 2022, then climbed by 8.76% to $609.5 million in 2023, then advanced by 7.58% to $655.7 million in 2024, then advanced by 5.97% to $694.9 million in 2025, then increased by 2.34% to $711.1 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $711.1 million, $700.3 million, and $694.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.